Breaking News Instant updates and real-time market news.

FOSL

Fossil

$9.04

0.65 (7.75%)

, CCS

Century Communities

$29.30

0.35 (1.21%)

17:34
02/13/18
02/13
17:34
02/13/18
17:34

On The Fly: After Hours Movers

UP AFTER EARNINGS: Fossil Group (FOSL), up 66.5%... Century Communities (CCS), up 8.8%... Twilio (TWLO), up 6.9%... Carbonite (CARB), up 6%... Baidu (BIDU), up 4.8%... Diamondback Energy (FANG), up 4.3%... Western Union (WU), up 3.7%. ALSO HIGHER: Chipotle (CMG), up 11.6% after it named Taco Bell's Brian Niccol as its next CEO... Infinity Property (IPCC), up 7% after it agreed to be acquired by Kemper (KMPR) in a $1.4B transaction. DOWN AFTER EARNINGS: ChannelAdvisor (ECOM), down 11.8%... Neurocrine Biosciences (NBIX), down 5.7%... Occidental Petroleum (OXY), down 3.5%... Omega Healthcare (OHI), down 3.2%. ALSO LOWER: Tetraphase (TTPH), down 59.1% after it said that its IGNITE3 trial did not achieve its co-primary endpoints... Pieris Pharmaceuticals (PIRS), down 10.1% after it filed to sell common stock.

FOSL

Fossil

$9.04

0.65 (7.75%)

CCS

Century Communities

$29.30

0.35 (1.21%)

TWLO

Twilio

$26.44

0.65 (2.52%)

CARB

Carbonite

$21.70

0.55 (2.60%)

BIDU

Baidu

$225.60

3.96 (1.79%)

FANG

Diamondback Energy

$115.03

-0.98 (-0.84%)

WU

Western Union

$19.75

-0.02 (-0.10%)

CMG

Chipotle

$251.33

-3.12 (-1.23%)

IPCC

Infinity Property

$96.05

-1 (-1.03%)

KMPR

Kemper

$57.55

-0.2 (-0.35%)

ECOM

ChannelAdvisor

$9.35

-0.05 (-0.53%)

NBIX

Neurocrine

$83.69

1.52 (1.85%)

OXY

Occidental Petroleum

$69.72

-0.15 (-0.21%)

OHI

Omega Healthcare

$26.96

0.58 (2.20%)

TTPH

Tetraphase

$5.43

-0.03 (-0.55%)

PIRS

Pieris Pharmaceuticals

$9.45

0.57 (6.42%)

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 13

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 20

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 08

    Mar

  • 04

    Apr

  • 30

    May

  • 14

    Feb

FOSL Fossil
$9.04

0.65 (7.75%)

01/05/18
BUCK
01/05/18
DOWNGRADE
Target $5
BUCK
Underperform
Fossil downgraded to Underperform, expectations high, says Buckingham
As previously reported, Buckingham downgraded Fossil to Underperform form Neutral and maintained a $5 price target. Analyst Scott Krasik believes higher expectations from tax reform are built into current valuation.
08/09/17
BOFA
08/09/17
NO CHANGE
Target $7
BOFA
Underperform
Fossil price target cut to $7 from $10 at BofA/Merrill
BofA/Merrill analyst Heather Blasky lowered Fossil's price target to $7 from $10 saying weak traditional watch sales continued to offset wearables growth as Q2 revenues missed across all regions. The analyst said gross margin erosion moderated but promotional activity remains elevated and he is concerned about deflationary pressures. Blasky reiterated his Underperform rating and the company is not immune to the "waning" watch cycle.
09/18/17
WELS
09/18/17
NO CHANGE
WELS
Retail seems to be stabilizing, says Wells Fargo
Wells Fargo analyst Ike Boruchow says that while it still seems too early to call for a robust recovery in retail fundamentals, the industry does seem to be stabilizing, with Q2 sales and EPS trends generally better than Q1 across the board. Further, store traffic has improved each month since February and management teams have taken a generally upbeat tone regarding back-to-school in recent public commentary, he adds. So, with solid traffic and favorable weather during the key back-to-school selling season, the analyst believes inventories could find themselves in good shape heading into the holidays and momentum appears to be on retail's side. Boruchow points out that according to his index, PVH Corp. (PVH) continues to be the ''most loved'' retailer in his universe, followed by TJX (TJX), Canada Goose (GOOS), and Steven Madden (SHOO), while Foot Locker (FL), Fossil (FOSL), and Finish Line (FINL) are the ''least loved'' names this month.
01/05/18
BUCK
01/05/18
DOWNGRADE
BUCK
Underperform
Fossil downgraded to Underperform from Neutral at Buckingham
CCS Century Communities
$29.30

0.35 (1.21%)

09/14/17
09/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. VMware (VMW) upgraded to Overweight from Equal Weight at Barclays with analyst Raimo Lenschow saying the stock looks undervalued as the thesis that VMware will lose market share as workloads move to the public cloud no longer seems valid, Lenschow tells investors in a research note. 2. Ryder (R) upgraded to Overweight from Sector Weight at KeyBanc with analyst Todd Fowler saying he believes the company's earnings path is improving after channel checks indicated near-term rental activity is at the high end of seasonal variations. 3. Century Communities (CCS) and Beazer Homes (BZH) were upgraded to Overweight from Neutral at JPMorgan. 4. Southern Company (SO) upgraded to Buy from Neutral at Guggenheim. 5. Air Products (APD) upgraded to Positive from Neutral at Susquehanna. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/17
JPMS
09/14/17
UPGRADE
Target $32
JPMS
Overweight
Century Communities upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Michael Rehaut upgraded Century Communities (CCS) to Overweight saying the relative valuation looks attractive. The analyst expects Century to post above average gross and operating margin expansion. He raised his price target for the shares to $32 from $28. Rehaut this morning also upgraded Beazer Homes (BZH) to Overweight and downgraded Toll Brothers (TOL) to Neutral. His top pick in the Homebuilding sector is PulteGroup (PHM).
08/08/17
SBSH
08/08/17
INITIATION
Target $30
SBSH
Buy
Century Communities resumed with a Buy at Citi
Citi analyst Will Randow resumed coverage of Century Communities with a Buy rating and raised his price target for the shares to $30 from $28.
12/29/17
WEDB
12/29/17
NO CHANGE
WEDB
Wedbush raises homebuilder price targets due to new tax bill
Wedbush analyst Jay McCanless increased his price targets on homebuilders by an average of 13.6% to reflect the potential impacts from the new tax bill, though he noted that his estimates and targets could need to be adjusted as companies begin reporting earnings giving specific tax guidance. He made the largest target increases to PulteGroup (PHM), Century Communities (CCS) and Taylor Morrison (TMHC), he noted. Other publicly traded companies in the space include Beazer Homes (BZH), CalAtlantic (CAA), D.R. Horton (DHI), Hovnanian (HOV), KB Home (KBH), Lennar (LEN), M.D.C. Holdings (MDC) and Toll Brothers (TOL).
TWLO Twilio
$26.44

0.65 (2.52%)

09/27/17
OPCO
09/27/17
NO CHANGE
OPCO
Outperform
Twilio should be bought on weakness, says Oppenheimer
Oppenheimer analyst Ittai Kidron notes that Amazon's (AMZN) AWS has announced the addition of global two-way text messaging capabilities to Pinpoint, its suite of user communication tools. The analyst believes investor fears that this will compete with Twilio (TWLO) are incorrect. While there is no "Powered by Twilio" branding, AWS's new Pinpoint SMS capability is powered on the back-end by Twilio's platform, he contends, noting the close relationship that Twilio has with AWS. Given Twilio's presence behind the scenes, Kidron would view the announcement as a positive for Twilio and would be aggressive buyers on any weakness. He reiterates an Outperform rating on Twilio's shares.
09/27/17
NORL
09/27/17
NO CHANGE
Target $9.5
NORL
Outperform
Vonage, Twilio enable Amazon's PinPoint text messaging, says Northland
Amazon (AMZN) announced yesterday that it has added two-way text messaging to its Pinpoint customer engagement service, which leverages the company's simple notification service, or SNS, capabilities, Northland analyst Michael Latimore tells investors in a research note. Vonage (VG) and Twilio (TWLO) enable SNS and thus, the Pinpoint customer engagement text messaging service, Latimore writes. He notes that Vonage also partners with Amazon on Chime conferencing and Essentials. The analyst has an Outperform rating on Vonage with a $9.50 price target. The stock in early trading is up 24c to $8.13.
12/06/17
BARD
12/06/17
NO CHANGE
Target $37
BARD
Outperform
Twilio investor day tone positive, says Baird
Baird analyst William Power said the overall tone of Twilio's investor day was positive. He said he remains positive on the company's competitive position and long-term growth opportunity fueled by increasing cloud communications use cases. He also remains positive on its stronger revenue growth and ability to improve margins long term. Power reiterated his Outperform rating and $37 price target on Twilio shares.
01/18/18
KEYB
01/18/18
NO CHANGE
KEYB
Cost savings emerge as 'killer app' for artificial intelligence, says KeyBanc
Over the past 35 days, KeyBanc analyst Brent Bracelin hosted meetings at Adobe (ADBE), Autodesk (ADSK), Algorithmia, Cloudera (CLDR), Coupa (COUP), Facebook (FB), Guidewire (GWRE), Netflix (NFLX), NVIDIA (NVDA), Salesforce (CRM), SAP, Synopsys (SNPS), Twilio (TWLO), Tableau (DATA), Talend (TLND), Veeva (VEEV), Workday (WDAY), and Zendesk (ZEN) as part of an AI & Cloud-themed field trip. The analyst notes that cost savings have emerged as the "killer app" for artificial intelligence, and large enterprise interest in migrating back-office apps to cloud has been slow, but is picking up, conversational AI and bot activity is yielding real cost savings. Further, Bracelin sees 2018 as a defining year for enterprise AI applications, and is most impressed by enterprise AI initiatives at Microsoft (MSFT), Zendesk, Guidewire, and Adobe.
CARB Carbonite
$21.70

0.55 (2.60%)

06/26/17
LEHM
06/26/17
INITIATION
Target $26
LEHM
Equal Weight
Carbonite initiated with an Equal Weight at Barclays
Barclays analyst Saket Kalia started Carbonite with an Equal Weight rating and $26 price target.
06/26/17
06/26/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PRA Health (PRAH) initiated with a Buy at BofA/Merrill by analyst Derik de Bruin , who cited its flexible and competitive CRO offerings, positive CRO industry fundamentals, and above average growth. 2. Cutera (CUTR) initiated with a Buy at Roth Capital by analyst Chris Lewis, who believes the company is well-positioned for increased U.S. productivity and more substantial profitability. He also views Cutera as a potentially "attractive" takeover target. 3. LyondellBasell (LYB) initiated with a Buy and $101 price target at HSBC by analyst Sriharsha Pappu. 4. Carbonite (CARB) initiated with an Equal Weight by Barclays analyst Saket Kalia, who set a $26 price target on the stock. 5. Green Dot (GDOT) initiated with a Hold at Lake Street by analyst Josh Elving. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/17/17
JMPS
10/17/17
INITIATION
Target $30
JMPS
Outperform
Carbonite initiated with an Outperform at JMP Securities
JMP Securities analyst Erik Suppiger started Carbonite with an Outperform rating and $30 price target, stating that his channel checks with partners suggest the company has a premier brand and offers a differentiated product. Though the stock is up close to 50% over the last year, Suppiger said he believes there is room for continued upside.
11/27/17
JMPS
11/27/17
NO CHANGE
JMPS
Outperform
JMP Securities reiterates Outperform rating on Carbonite after Barracuda buyout
After Barracuda Networks (CUDA) announced a deal to be acquired by Thoma Bravo for $27.55 per share in cash, JMP Securities analyst Erik Suppiger reiterated his Outperform rating on Carbonite (CARB), saying that the deal validates the attraction of the small and midsize business data protection and security market. He also noted that Carbonite trades at a 33% discount to the deal price agreed to for Barracuda on a revenue multiple basis and a 34% discount on an earnings multiple basis based on 2018 estimates.
BIDU Baidu
$225.60

3.96 (1.79%)

02/05/18
OTRG
02/05/18
DOWNGRADE
OTRG
Mixed
Baidu downgraded to Mixed from Positive at OTR Global (pre-open)
Pre-open, OTR Global downgraded Baidu to Mixed from Positive following checks indicating search growth came under pressure in Q4 2017 and was lower than expectations due to budget shifts towards ecommerce and social media platforms.
01/29/18
NOMU
01/29/18
DOWNGRADE
NOMU
Neutral
Baidu downgraded to Neutral from Buy at Nomura Instinet
01/23/18
JEFF
01/23/18
DOWNGRADE
Target $285
JEFF
Hold
Jefferies wants better entry point, downgrades Baidu to Hold
Jefferies analyst Karen Chan downgraded Baidu (BIDU) to Hold from Buy and lowered her price target for the shares to $285 from $291. The Chinese technology company closed yesterday down $1.64 to $254.34. The analyst says that while she remains positive on Baidu's "leading" artificial intelligence position, she prefers to wait for a better entry point following the stock's rebound from lows. In China Internet, Chan's top picks are Tencent (TCEHY), Alibaba (BABA) and Weibo (WB). Momo (MOMO) remains the analyst's preferred mid-cap pick.
01/29/18
NOMU
01/29/18
DOWNGRADE
Target $276
NOMU
Neutral
Nomura downgrades Baidu to Neutral after 50% share rally
Nomura Instinet analyst Jialong Shi downgraded Baidu to Neutral from Buy and cut his price target for the shares to $276 from $301. The stock in afternoon trading is down 2% to $254.88. The analyst lowered his fiscal 2018 estimates by 8% to reflect Baidu's ramp-up in spending to acquire user traffic and video content. He believes the stock's 50% rise over the past 12 months largely prices in the company's positive developments. Shi prefers shares of Tencent (TCEHY) at current valuation levels.
FANG Diamondback Energy
$115.03

-0.98 (-0.84%)

01/23/18
FBCO
01/23/18
NO CHANGE
Target $143
FBCO
Outperform
Diamondback Energy price target raised to $143 from $123 at Credit Suisse
Credit Suisse analyst Betty Jiang raised her price target for Diamondback Energy to $143 from $123 on valuation. The analyst reiterates an Outperform rating on the shares.
02/01/18
DBAB
02/01/18
INITIATION
Target $162
DBAB
Buy
Diamondback Energy initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Nitin Kumar started Diamondback Energy with a Buy rating and $162 price target.
02/01/18
DBAB
02/01/18
INITIATION
DBAB
Deutsche names Parsley, Diamondback, Cimarex top E&P picks
Deutsche analyst Nitin Kumar rolled out coverage on 17 stocks in the U.S. Exploration & Production after the close today. His top picks are Parsley Energy (PE), Diamondback Energy (FANG) and Cimarex Energy (XEC).
02/06/18
RILY
02/06/18
INITIATION
Target $150
RILY
Neutral
Diamondback Energy initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Rehan Rashid started Diamondback Energy with a Neutral rating and $150 price target.
WU Western Union
$19.75

-0.02 (-0.10%)

01/08/18
01/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Technologies (UTX) upgraded to Buy from Neutral at Goldman Sachs with analyst Noah Poponak saying he believes United Technologies is within the year of maximum new engine loss on Geared Turbofan engines, or GTFs, and thinks the market will begin to look beyond that peak loss and give increased consideration to substantial longer-term cash flows. 2. Caterpillar (CAT) upgraded to Overweight from Neutral at JPMorgan with analyst Ann Duignan saying she believes the stock still has "significant upside" despite the outperformance in 2017. 3. Flir Systems (FLIR) upgraded to Buy from Hold at SunTrust with analyst Michael Ciarmoli citing the company's realigned segment structure under the new management team with a sharper focus on the larger government and industrial end-markets, forecasting outperformance driven by RAID order flow and new Department of Defense procurement initiatives. 4. Applied Materials (AMAT) upgraded to Strong Buy from Buy at Needham with analyst Y. Edwin Mok saying he is positive on the company's "balanced WFE exposure across segments" amid the likelihood of moderating NAND growth. 5. Western Union (WU) upgraded to Neutral from Negative at Susquehanna with analyst James Friedman saying he believes the company may be working with Ripple Labs to potentially implement blockchain applications in remittance and sees that as a possible accelerator with business-to-business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/18
SUSQ
01/08/18
UPGRADE
Target $21
SUSQ
Neutral
Western Union upgraded to Neutral at Susquehanna
As previously reported, Susquehanna analyst James Friedman upgraded Western Union to Neutral from Negative. He believes the company may be working with Ripple Labs to potentially implement blockchain applications in remittance and sees that as a possible accelerator with business-to-business. Friedman raised his price target to $21 from $17 on Western Union shares.
01/08/18
SUSQ
01/08/18
UPGRADE
SUSQ
Neutral
Western Union upgraded to Neutral from Negative at Susquehanna
12/14/17
12/14/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CBS (CBS) initiated with an Overweight at Stephens. 2. Floor & Decor (FND) initiated with a Buy at Stifel. 3. Tronox (TROX) initiated with an Overweight at Barclays. 4. LivePerson (LPSN) initiated with a Buy at B. Riley FBR. 5. Western Union (WU) assumed with a Sell at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CMG Chipotle
$251.33

-3.12 (-1.23%)

02/07/18
MAXM
02/07/18
NO CHANGE
Target $410
MAXM
Buy
Chipotle price target lowered to $410 from $425 at Maxim
Maxim analyst Stephen Anderson lowered his price target on Chipotle to $410 after Q4 earnings, saying the 0.9% SSS were below his target of 1.5% while also pointing to increased restaurant level investments. The analyst keeps his Buy rating and also maintains his FY18 SSS view of 4%-5%, stating that Chipotle has comps drivers ahead.
02/07/18
FBCO
02/07/18
NO CHANGE
Target $275
FBCO
Neutral
Chipotle price target lowered to $275 from $330 at Credit Suisse
Credit Suisse analyst Jason West lowered his price target for Chipotle to $275 from $330 following quarterly results. The analyst believes shares seem likely to remain range-bound until the new CEO is hired and his/her strategic turnaround can be assessed by the market. The analyst reiterates a Neutral rating on the shares.
02/07/18
BERN
02/07/18
NO CHANGE
Target $500
BERN
Outperform
Chipotle price target lowered to $500 from $564 at Bernstein
Bernstein analyst Sara Senatore lowered her price target for Chipotle to $500 from $564 as she lowers long-term margins to reflect stepped up investment. The analyst says that traffic holding steady despite a price increase is a "relief," and if Chipotle can avoid another safety scare, better executed advertising and growth in the 2nd make line should support topline. She reiterates an Outperform rating on the shares.
02/07/18
02/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wynn Resorts (WYNN) downgraded to Neutral from Buy at Roth Capital with analyst David Bain citing the news of Steve Wynn stepping down as Chairman and CEO. 2. Snap (SNAP) downgraded to Negative from Neutral at Susquehanna. 3. Chipotle (CMG) was downgraded to Sell from Hold at Stifel and to Neutral from Buy at Mizuho. 4. Cboe Global Markets (CBOE) was downgraded to Neutral from Overweight at JPMorgan and to Neutral from Buy at Goldman Sachs. 5. Macom (MTSI) was downgraded to Neutral from Overweight at JPMorgan and to Equal Weight from Overweight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IPCC Infinity Property
$96.05

-1 (-1.03%)

07/13/17
RAJA
07/13/17
UPGRADE
Target $105
RAJA
Outperform
Infinity Property upgraded on improving auto cycle profits at Raymond James
As previously reported, Raymond James upgraded Infinity Property to Outperform from Market Perform and established a $105 price target. Analyst Gregory Peters believes Infinity is one of the best positioned small cap peers to benefit from emerging smartphone technology to monitor and price for distracted driving over the next 24 months. He expects management's focus on new technology adoption and current favorable market conditions to result in the company meeting or exceeding its 10% ROE target over the next 12 months.
07/13/17
RAJA
07/13/17
UPGRADE
RAJA
Outperform
Infinity Property upgraded to Outperform from Market Perform at Raymond James
KMPR Kemper
$57.55

-0.2 (-0.35%)

08/03/17
08/03/17
UPGRADE

Strong Buy
Kemper upgraded to Strong Buy on non-auto turn at Raymond James
As previously reported, Raymond James upgraded Kemper to Strong Buy from Market Perform and established a $55 price target. Analyst Gregory Peters believes the non-standard auto business is beginning to turn following pricing, re-underwriting and claims initiatives. Management is working on improving the preferred auto business and believes ROE will gradually improve through 2019 given the combination of positive pricing in personal auto, and management's strategic initiatives.
08/03/17
RAJA
08/03/17
UPGRADE
RAJA
Strong Buy
Kemper upgraded to Strong Buy from Market Perform at Raymond James
ECOM ChannelAdvisor
$9.35

-0.05 (-0.53%)

08/31/17
08/31/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FMC Corporation (FMC) upgraded to Buy from Underperform at BofA/Merrill with analyst Steve Byrne double upgrading FMC following survey results that indicate ag sales are likely to increase 1-3% rather than decline 1-3%, as previously expected. 2. Owens Corning (OC) upgraded to Outperform from Market Perform at Wells Fargo with analyst Stephen East saying he sees an "inexpensive valuation" versus peers and has increased comfort in Owens' ability to achieve or surpass this year's targets. Hurricane Harvey is a boost to the company's roofing business, but its insulation replacement "may be the bigger winner," East tells investors. 3. ChannelAdvisor (ECOM) upgraded to Overweight from Equal-Weight at First Analysis with analyst Lawrence Berlin citing increased confidence in the company's ability to accelerate growth and hit its mid-teen growth targets after meeting with management. 4. Abercrombie & Fitch (ANF) upgraded to Sector Perform from Underperform at RBC Capital with analyst Brian Tunick saying a return to profitability in the second half of 2017 is more likely following Q2 results that suggest that turnaround efforts are yielding results faster than anticipated. 5. Transocean (RIG) upgraded to Overweight from Equalweight at Capital One with analyst Joseph Gibney saying the group is exhibiting some modest "green shoots" and sees upside to Transocean on a relative basis even in a long/measured recovery and some semblance of contracting pickup. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/02/18
KEYB
01/02/18
NO CHANGE
KEYB
Shopify, PTC among favorite ideas in vertical software, says KeyBanc
KeyBanc analyst Monika Garg expects vertical software companies to outperform in 2018 due to their deep vertical moats, which can help derive high market share and margins. The analyst's favorite ideas for 2018 are Shopify (SHOP), PTC (PTC), 2U (TWOU), and RealPage (RP.) Due to headwinds for brick-and-mortar retailers, she remains cautious on Manhattan Associates (MANH), SPS Commerce (SPSC), ChannelAdvisor (ECOM), and CommerceHub (CHUBA).
02/06/18
DADA
02/06/18
UPGRADE
Target $11.5
DADA
Buy
ChannelAdvisor upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Tom Forte upgraded ChannelAdvisor to Buy from Neutral and kept his $11.50 price target ahead of Q4 earnings next week. Forte cites several catalysts in his rating change, including the management's strategy on focusing on larger clients for its platform whose sales should accelerate this year, more top-line upside after the acquisition of HubLogix in 2017, and faster than expected growth from exports to China.
09/22/17
DADA
09/22/17
INITIATION
Target $12.5
DADA
Neutral
ChannelAdvisor initiated with a Neutral at DA Davidson
DA Davidson analyst Tom Forte started ChannelAdvisor with a Neutral rating and $12.50 price target.
NBIX Neurocrine
$83.69

1.52 (1.85%)

01/16/18
NEED
01/16/18
NO CHANGE
Target $95
NEED
Buy
Neurocrine price target raised to $95 from $86 at Needham
Needham analyst Alan Carr raised his price target on Neurocrine Biosciences to $95 after the company pre-announced 2017 revenue and INGREZZA sales last week. The analyst says the above-estimate print was in part the result of a delay in the uptake of the 80mg capsule that is less expensive than the 40mg. Carr believes that the launch is proceeding well, warranting an increase in FY18 revenue while raising his 2018-2020 INGREZZA sales forecast to $350M from $340M. The analyst keeps his Buy rating on Neurocrine Biosciences.
01/16/18
OPCO
01/16/18
NO CHANGE
Target $95
OPCO
Outperform
Neurocrine price target raised to $95 from $85 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Neurocrine to $95 from $85 based on preliminary Q4 results increasing his revenue and earnings estimates. The analyst reiterates an Outperform rating on the shares.
01/05/18
JEFF
01/05/18
NO CHANGE
Target $105
JEFF
Buy
Neurocrine price target raised to $105 from $81 at Jefferies
Jefferies analyst Biren Amin raised his price target for Neurocrine Biosciences (NBIX) to $105 following his fourth proprietary survey on tardive dyskinesia. The respondents provided bullish estimates compared to past surveys, which sees prescribing possibly doubling from current levels for Neurocrine's Ingrezza and Teva's (TEVA) Austedo in both mod-severe and mild Tardive Dyskinesia by the end of 2018, Amin tells investors in a research note. The analyst expects Ingrezza to lead Austedo in market share raised his revenue estimates for Neurocrine. Amin keeps a Buy rating on the shares.
01/22/18
OPCO
01/22/18
NO CHANGE
OPCO
Neurocrine, CymaBay could benefit from increased M&A, says Oppenheimer
Oppenheimer analyst Jay Olson notes that driven by tax reform and cash repatriation, Biotech investors expect increased M&A activity. The analyst believes tax reform with cash repatriation will increase firepower of potential buyers, and points out that managements stated interest in targets with strategic fit. In his coverage universe, Olson believes Neurocrine (NBIX), Portola Pharmaceuticals (PTLA) and CymaBay (CBAY) shares could benefit from increased M&A based on their therapeutic areas and strategic fit.
OXY Occidental Petroleum
$69.72

-0.15 (-0.21%)

01/17/18
MACQ
01/17/18
INITIATION
Target $75
MACQ
Neutral
Occidental Petroleum initiated with a Neutral at Macquarie
Macquarie analyst Kate Sloan initiated Occidental Petroleum with a Neutral and $75 price target. Sloan said Occidental has a high break-even and does not cover its dividend at current oil forecasts.
01/04/18
BOFA
01/04/18
DOWNGRADE
BOFA
Neutral
Occidental Petroleum downgraded to Neutral from Buy at BofA/Merrill
01/04/18
BOFA
01/04/18
DOWNGRADE
Target $80
BOFA
Neutral
Occidental Petroleum downgraded to Neutral on valuation at BofA/Merrill
As previously reported, BofA/Merrill downgraded Occidental Petroleum to Neutral from Buy and increased its price target to $80 from $79. Analyst Doug Leggate said the strong recovery in shares appropriately values lower US corporate taxes in its domestic Chemicals and midstream business.
01/22/18
SBSH
01/22/18
UPGRADE
Target $73
SBSH
Neutral
Occidental Petroleum upgraded to Neutral from Sell at Citi
Citi analyst Robert Morris upgraded Occidental Petroleum (OXY) to Neutral and raised his price target for the shares to $73 from $64. The upgrades follows the analyst's estimate increases last week. His highest conviction pair trade into Q4 earnings is long Occidental versus Hess Corp. (HES). He expects Hess to miss on production and to lower its 2018 guidance due to shut-ins in the deepwater Gulf of Mexico and weather-related issues in the Bakken. Occidental, on the other hand, is "hitting on all cylinders," Morris writes.
OHI Omega Healthcare
$26.96

0.58 (2.20%)

12/21/17
CANT
12/21/17
INITIATION
Target $34
CANT
Overweight
Cantor starts Omega Healthcare at Overweight, highlights 9.1% yield
Cantor Fitzgerald analyst Joseph France last night initiated Omega Healthcare Investors with an Overweight rating and $34 price target. Skilled nursing is attractive in a value-based reimbursement environment and the stock's 9.1% yield compensates investors for the operator risk that could be resolved by the middle of 2018, France told investors in a research note. The analyst says the liquidity issues confronting several of Omega Healthcare's operators are real, but not uncommon.
12/21/17
JEFF
12/21/17
DOWNGRADE
Target $22
JEFF
Underperform
Omega Healthcare downgraded to Underperform from Hold at Jefferies
Jefferies analyst Omotayo Okusanya downgraded Omega Healthcare to Underperform and lowered his price target for the shares to $22 from $26. The analyst is taking a more conservative view with the company given the "increasingly difficult" environment for skilled nursing facility operators. He thinks Omega could see more tenant issues in 2018.
12/21/17
JEFF
12/21/17
DOWNGRADE
JEFF
Underperform
Omega Healthcare downgraded to Underperform from Hold at Jefferies
12/20/17
CANT
12/20/17
INITIATION
Target $34
CANT
Overweight
Omega Healthcare initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated Omega Healthcare with and Overweight and $34 price target.
TTPH Tetraphase
$5.43

-0.03 (-0.55%)

02/06/18
HCWC
02/06/18
NO CHANGE
Target $17
HCWC
Buy
Tetraphase risk/reward 'highly favorable' into data, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce says the imminent data readout of the Phase 3 Ignite3 study is a "major potential catalyst" for the shares of Tetraphase Pharmaceuticals. The analyst believes the trial "will be a solid, clean win." He views the Ignite3 readout as a "highly favorable" risk/reward equity position, with a risk-adjusted expected value of the shares of about $9.50 post-data. The analyst affirms a Buy rating on Tetraphase with a $17 price target.
02/12/18
02/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. First Solar (FSLR) initiated with an Underperform at Credit Suisse. The firm also started SunPower (SPWR) with a Neutral and Sunrun (RUN) with an Outperform. 2. Genocea (GNCA) initiated with an Outperform at Baird. 3. Tetraphase (TTPH) initiated with a Buy at B. Riley FBR. 4. Aspen Group (ASPU) initiated with a Buy at Craig-Hallum. 5. Vermilion Energy (VET) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
RILY
02/12/18
INITIATION
Target $11
RILY
Buy
Tetraphase initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Tetraphase Pharmaceuticals with a Buy rating and $11 price target. The analyst sees "broad" antibiotic potential for the company and believes its Phase III readout in Q1 is de-risked.
11/06/17
HCWC
11/06/17
NO CHANGE
Target $17
HCWC
Buy
Tetraphase price target raised to $17 from $15 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Tetraphase to $17 saying the six corporate milestones laid out in the Q3 earnings release "highlight several potential value-creating stock catalysts in 2018." The analyst believes the company is well positioned to achieve the milestones. He keeps a Buy rating on the shares.
PIRS Pieris Pharmaceuticals
$9.45

0.57 (6.42%)

05/04/17
OPCO
05/04/17
NO CHANGE
OPCO
Outperform
Oppenheimer stays bullish on PRS-060 after Pieris Pharma, AstraZeneca deal
Oppenheimer analyst Hartaj Singh notes that Pieris Pharmaceuticals (PIRS) announced an "impressive deal" with AstraZeneca (AZN) for its preclinical Anticalin candidate PRS-060 targeting IL-4Ralpha. The analyst is impressed with the size of the upfront payment for a preclinical asset, the choice of AstraZeneca for a partner, and the fact that IL-4Ralpha has become a hot target in light of Regeneron's (REGN) recent approval of Dupixent. Singh has been very positive on PRS-060 previously and stays bullish, reiterating an Outperform rating on Pieris Pharmaceuticals' shares.
01/16/18
HCWC
01/16/18
NO CHANGE
Target $12
HCWC
Buy
Pieris Pharmaceuticals price target raised to $12 from $9 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Pieris Pharmaceuticals to $12 after sitting down with management. The company has three diverse clinical programs in the pipeline with data expected in 2018, Pantginis tells investors in a research note. The analyst keeps a Buy rating on the shares.
05/30/17
RODM
05/30/17
INITIATION
Target $9
RODM
Buy
Pieris Pharmaceuticals initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Pieris Pharmaceuticals with a Buy rating and $9 price target. The company's class of biologics called anticalins have already generated a "broad pipeline and attracted several partnerships," the analyst writes.
05/30/17
05/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ovid Therapeutics (OVID) was initiated with a Buy at Citi and an Outperform at William Blair, JMP Securities, and Cowen. 2. Antero Midstream Partners (AM) was resumed with an Overweight at Morgan Stanley, initiated with an Outperform at Credit Suisse, and reinstated with an Overweight at Barclays. 3. Antero Midstream GP (AMGP) was initiated with an Overweight at Morgan Stanley, JPMorgan, and Barclays, an Outperform at Baird and Credit Suisse, a Market Perform at Wells Fargo, a Strong Buy at Raymond James, a Buy at Goldman Sachs, Ladenburg, and DA Davidson, as well as a Hold at Stifel. 4. Biohaven Pharmaceutical (BHVN) was initiated with an Outperform at William Blair, an Overweight at Piper Jaffray and Barclays, as well as a Buy at Needham. 5. Pieris Pharmaceuticals (PIRS) initiated with a Buy at Rodman & Renshaw. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:26
02/24/18
02/24
16:26
02/24/18
16:26
Hot Stocks
Buffett believes Berkshire can handle $400B mega-catastrophe »

In his annual letter to…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:19
02/24/18
02/24
16:19
02/24/18
16:19
Periodicals
Buffet says laments inability to find targets for Berkshire to buy, Reuters says »

Warren Buffett lamented…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:16
02/24/18
02/24
16:16
02/24/18
16:16
Periodicals
Berkshire Hathaway reports record profit fueled by tax reform, Reuters says »

Berkshire Hathaway…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$32.66

0.55 (1.71%)

16:12
02/24/18
02/24
16:12
02/24/18
16:12
Periodicals
Twitter's SoundCloud investment officially wiped out, Recode reports »

Twitter has written off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

AAPL

Apple

$175.50

3 (1.74%)

16:08
02/24/18
02/24
16:08
02/24/18
16:08
Periodicals
Apple to store sensitive encryption keys in China, WSJ reports »

Apple will start to store…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

16:00
02/24/18
02/24
16:00
02/24/18
16:00
Periodicals
Volkswagen's U.S. unit settles emissions suit, Reuters reports »

Volkswagen's unit in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

, UAL

United Continental

$67.57

0.87 (1.30%)

15:56
02/24/18
02/24
15:56
02/24/18
15:56
Periodicals
Delta, United Airlines cut ties with NRA, Reuters reports »

Delta Air Lines (DAL) and…

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

UAL

United Continental

$67.57

0.87 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 30

    May

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

15:53
02/24/18
02/24
15:53
02/24/18
15:53
Earnings
Berkshire Hathaway reports Q4 operating EPS $3,338, consensus $2,622.23 »

Reports FY17 operating…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$94.70

0.33 (0.35%)

, T

AT&T

$36.72

0.25 (0.69%)

15:44
02/24/18
02/24
15:44
02/24/18
15:44
Periodicals
May be time to consider Time Warner, Barron's says »

Time Warner (TWX) shares…

TWX

Time Warner

$94.70

0.33 (0.35%)

T

AT&T

$36.72

0.25 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 23

    Apr

JKHY

Jack Henry

$121.95

1.79 (1.49%)

12:59
02/24/18
02/24
12:59
02/24/18
12:59
Conference/Events
Jack Henry management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

PFBC

Preferred Bank

$64.05

0.86 (1.36%)

12:52
02/24/18
02/24
12:52
02/24/18
12:52
Conference/Events
Preferred Bank management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Mar

  • 24

    Sep

R

Ryder

$74.54

0.19 (0.26%)

12:47
02/24/18
02/24
12:47
02/24/18
12:47
Conference/Events
Ryder management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

ASPU

Aspen Group

$8.85

1.48 (20.08%)

12:29
02/24/18
02/24
12:29
02/24/18
12:29
Conference/Events
Aspen Group to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

TWTR

Twitter

$32.66

0.55 (1.71%)

, AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

10:47
02/24/18
02/24
10:47
02/24/18
10:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWTR

Twitter

$32.66

0.55 (1.71%)

AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

RGR

Sturm, Ruger

$49.90

0.9 (1.84%)

X

U.S. Steel

$43.52

0.54 (1.26%)

STLD

Steel Dynamics

$47.47

-0.53 (-1.10%)

NUE

Nucor

$66.94

-0.01 (-0.01%)

AKS

AK Steel

$5.50

-0.12 (-2.14%)

AET

Aetna

$175.55

0.49 (0.28%)

ANTM

Anthem

$235.24

1.56 (0.67%)

CNC

Centene

$100.45

0.96 (0.96%)

CI

Cigna

$194.79

2.89 (1.51%)

HNT

Health Net

HUM

Humana

$271.19

3.38 (1.26%)

MOH

Molina Healthcare

$72.94

1.38 (1.93%)

UNH

UnitedHealth

$230.16

3.07 (1.35%)

WCG

WellCare

$192.05

0.03 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 07

    Mar

  • 13

    Mar

  • 16

    Apr

  • 30

    May

DBX

Dropbox

, SNAP

Snap

$17.45

-0.06 (-0.34%)

09:49
02/24/18
02/24
09:49
02/24/18
09:49
Periodicals
Dropbox IPO bodes well, Barron's says »

In a follow-up article…

DBX

Dropbox

SNAP

Snap

$17.45

-0.06 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

IPG

Interpublic Group

$24.24

0.3 (1.25%)

, OMC

Omnicom

$77.31

0.52 (0.68%)

09:42
02/24/18
02/24
09:42
02/24/18
09:42
Periodicals
Advertising companies cheaper than usual, Barron's says »

After a tumble last year,…

IPG

Interpublic Group

$24.24

0.3 (1.25%)

OMC

Omnicom

$77.31

0.52 (0.68%)

PUBGY

Publicis

$18.82

0.09 (0.48%)

WPP

WPP

$95.30

0.93 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 05

    Mar

MSFT

Microsoft

$94.06

2.33 (2.54%)

, INTC

Intel

$47.73

1.93 (4.21%)

09:36
02/24/18
02/24
09:36
02/24/18
09:36
Periodicals
Quantum computing soon to be reality, Barron's says »

Microsoft (MSFT) predicts…

MSFT

Microsoft

$94.06

2.33 (2.54%)

INTC

Intel

$47.73

1.93 (4.21%)

NVDA

Nvidia

$245.93

3.78 (1.56%)

MU

Micron

$46.53

2.28 (5.15%)

GOOG

Alphabet

$1,126.79

20.16 (1.82%)

GOOGL

Alphabet Class A

$1,128.09

18.19 (1.64%)

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 28

    Feb

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 30

    May

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

09:26
02/24/18
02/24
09:26
02/24/18
09:26
Periodicals
Many downsides when Amazon's HQ2 comes to town, Barron's says »

As Amazon decides on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.